Jiahe Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiahe Liao has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jia-Qi Chen
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China
6 shared publications - Jing Luo
National Center for Integrative Medicine, Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People’s Republic of China
6 shared publications - Qingwen Tao
National Center for Integrative Medicine, Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People’s Republic of China
6 shared publications - Yan Zhang
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China
5 shared publications - Jian-Ying Mbbs Yang
Graduate School, Beijing University of Chinese Medicine
4 shared publications - Xin-Bo Yu
Graduate School, Beijing University of Chinese Medicine
4 shared publications
Latest Publications
- 22 September 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 164
Association of clinical-immunologic clusters and anti-RNP/Ro52 antibody profiles with prognostic trajectories in primary Sjögren's disease
- 22 September 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 164
Association of clinical-immunologic clusters and anti-RNP/Ro52 antibody profiles with prognostic trajectories in primary Sjögren's disease
- Open Access
- 14 January 2026
- Published by Springer Nature in Biology of Sex Differences
- Vol. 17 (1)
Sex differences in primary Sjögren’s disease: prognostic impact on mortality and cancer
Objective: To assess the impact of sex on mortality and malignancy in patients with primary Sjögren’s disease (pSD). Methods: This ambispective cohort study included 1,182 pSD patients (1,025 women and 157 men) from the China–Japan Friendship Hospital between 2014–2023 and followed through 2024. Survival outcomes were estimated via Kaplan–Meier curves, and SMRs were calculated. Independent risk factors were identified via multivariate Cox regression, followed by stepwise Cox, sex-stratified and interaction analyses. Results: During follow-up, 125 deaths (10.6%) and 33 malignancies (2.8%) occurred, both of which were more common in men (log–rank tests, P < 0.001). Overall mortality was markedly higher in men (25.5%, SMR = 4.79) than in women (8.3%, SMR = 2.42). Male sex was independently associated with higher risk of mortality (HR = 1.998, P = 0.004) and cancer incidence (HR = 3.799, P = 0.001). Sex-stratified analyses revealed distinct death–associated factors: interstitial lung disease (ILD), pulmonary infection and ischemic stroke were independently associated with mortality in men, whereas older age, low C3, elevated C-reactive protein and total bilirubin (TBIL) levels were associated with mortality in women. With respect to cancer, longer disease duration, lymphadenopathy, lymphocytopenia, elevated TBIL and hypochloremia were independently associated with cancer risk in women, whereas no variables showed an independent association with cancer risk among men. Interaction analyses demonstrated additive interactions between male sex and elevated ESSDAI scores, as well as male sex and concomitant ILD, in relation to mortality. Conclusion: Compared with women, men with pSD presented greater risks and distinct risk profiles of death and malignancy. Moreover, male sex was independently associated with adverse outcomes and acted as an important effect modifier, highlighting the need for sex-specific risk stratification and clinical management. Trial registration: This ambispective cohort study was registered in the Clinical Trial Registry (ID: NCT06528197) on June 27, 2024 and conducted in accordance with the Declaration of Helsinki.
- 14 January 2026
- Published by Springer Nature in Biology of Sex Differences
- Vol. 17 (1)
Open AccessSex differences in primary Sjögren’s disease: prognostic impact on mortality and cancer
Objective: To assess the impact of sex on mortality and malignancy in patients with primary Sjögren’s disease (pSD). Methods: This ambispective cohort study included 1,182 pSD patients (1,025 women and 157 men) from the China–Japan Friendship Hospital between 2014–2023 and followed through 2024. Survival outcomes were estimated via Kaplan–Meier curves, and SMRs were calculated. Independent risk factors were identified via multivariate Cox regression, followed by stepwise Cox, sex-stratified and interaction analyses. Results: During follow-up, 125 deaths (10.6%) and 33 malignancies (2.8%) occurred, both of which were more common in men (log–rank tests, P < 0.001). Overall mortality was markedly higher in men (25.5%, SMR = 4.79) than in women (8.3%, SMR = 2.42). Male sex was independently associated with higher risk of mortality (HR = 1.998, P = 0.004) and cancer incidence (HR = 3.799, P = 0.001). Sex-stratified analyses revealed distinct death–associated factors: interstitial lung disease (ILD), pulmonary infection and ischemic stroke were independently associated with mortality in men, whereas older age, low C3, elevated C-reactive protein and total bilirubin (TBIL) levels were associated with mortality in women. With respect to cancer, longer disease duration, lymphadenopathy, lymphocytopenia, elevated TBIL and hypochloremia were independently associated with cancer risk in women, whereas no variables showed an independent association with cancer risk among men. Interaction analyses demonstrated additive interactions between male sex and elevated ESSDAI scores, as well as male sex and concomitant ILD, in relation to mortality. Conclusion: Compared with women, men with pSD presented greater risks and distinct risk profiles of death and malignancy. Moreover, male sex was independently associated with adverse outcomes and acted as an important effect modifier, highlighting the need for sex-specific risk stratification and clinical management. Trial registration: This ambispective cohort study was registered in the Clinical Trial Registry (ID: NCT06528197) on June 27, 2024 and conducted in accordance with the Declaration of Helsinki.
- 15 October 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (10) , e70432
Mendelian Randomization Suggests a Bidirectional Causal Relationship Between Sjögren's Syndrome and Interstitial Lung Disease
- 15 October 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (10) , e70432
Mendelian Randomization Suggests a Bidirectional Causal Relationship Between Sjögren's Syndrome and Interstitial Lung Disease
- Open Access
- 22 February 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (4) , 151-158
Disease Duration Affects the Clinical Phenotype of Primary Sjögren Syndrome
Objectives: To investigate the impact of disease duration on clinical phenotypes in Chinese patients with primary Sjögren syndrome (pSS) and examine the correlation between clinical phenotypes and onset age, age at diagnosis, and disease duration. Methods: Data from 952 patients diagnosed with pSS in China between January 2013 and March 2022 were analyzed based on medical records. Patients were categorized into 3 groups based on disease duration: short (p p p p p p < 0.05), anti-Ro52 (p < 0.05), and anti-SSB (p < 0.05) positivity than their control groups, with prevalence increasing with disease duration (p trend < 0.001). However, no differences were noted in the prevalence of interstitial lung disease and leukopenia between different disease duration groups after matching for age at onset, although differences were shown when matching for age at diagnosis. Conclusion: Longer disease duration in pSS patients correlates with increased prevalence of sicca symptoms, fatigue, and arthralgia and higher positivity of autoantibodies associated with pSS. However, the prevalence of interstitial lung disease and leukopenia did not correlate with disease duration after matching for age at onset.
- 22 February 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (4) , 151-158
Open AccessDisease Duration Affects the Clinical Phenotype of Primary Sjögren Syndrome
Objectives: To investigate the impact of disease duration on clinical phenotypes in Chinese patients with primary Sjögren syndrome (pSS) and examine the correlation between clinical phenotypes and onset age, age at diagnosis, and disease duration. Methods: Data from 952 patients diagnosed with pSS in China between January 2013 and March 2022 were analyzed based on medical records. Patients were categorized into 3 groups based on disease duration: short (p p p p p p < 0.05), anti-Ro52 (p < 0.05), and anti-SSB (p < 0.05) positivity than their control groups, with prevalence increasing with disease duration (p trend < 0.001). However, no differences were noted in the prevalence of interstitial lung disease and leukopenia between different disease duration groups after matching for age at onset, although differences were shown when matching for age at diagnosis. Conclusion: Longer disease duration in pSS patients correlates with increased prevalence of sicca symptoms, fatigue, and arthralgia and higher positivity of autoantibodies associated with pSS. However, the prevalence of interstitial lung disease and leukopenia did not correlate with disease duration after matching for age at onset.
- Open Access
A bibliometric analysis of primary Sjögren's syndrome-associated lymphoma from 1991 to 2022
- Open Access
- 17 April 2023
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 29 (5) , e78-e85
Sex Difference in Primary Sjögren Syndrome
Objectives: The aim of this study was to study clinical and biological differences between men and women with primary Sjögren syndrome (pSS) in China and perform a literature review to confirm if the clinical phenotypes are affected by sex in patients with pSS. Methods: Data from 961 patients with pSS treated at a tertiary hospital in China between January 2013 and March 2022 were analyzed based on medical records. Clinical characteristics, including disease manifestations and serological parameters of the disease, were compared between men and women with pSS using the Mann-Whitney U test and χ2 test. Results: This study included 140 (14.6%) men and 821 (85.4%) women with pSS. Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes, arthralgia, and dental caries (p < 0.05); higher erythrocyte sedimentation rate and immunoglobulin M levels (p < 0.05); higher prevalence of leukopenia, neutropenia, anemia, low complement 3, and low complement 4 (p < 0.05); and higher titers of antinuclear antibody, anti-Sjögren syndrome A, anti-Ro52, and rheumatoid factor positivity (p < 0.05) than men, whereas men with pSS had a higher prevalence of parotid enlargement and interstitial lung disease (p < 0.05). Conclusions: Women with pSS are associated with more dryness, cytopenia, hypocomplementemia, and autoantibody positivity. Although men with pSS probably have lighter sicca symptoms and lower immunoactivity and serologic responses, regular monitoring of interstitial lung disease in men is vital.
- 17 April 2023
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 29 (5) , e78-e85
Open AccessSex Difference in Primary Sjögren Syndrome
Objectives: The aim of this study was to study clinical and biological differences between men and women with primary Sjögren syndrome (pSS) in China and perform a literature review to confirm if the clinical phenotypes are affected by sex in patients with pSS. Methods: Data from 961 patients with pSS treated at a tertiary hospital in China between January 2013 and March 2022 were analyzed based on medical records. Clinical characteristics, including disease manifestations and serological parameters of the disease, were compared between men and women with pSS using the Mann-Whitney U test and χ2 test. Results: This study included 140 (14.6%) men and 821 (85.4%) women with pSS. Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes, arthralgia, and dental caries (p < 0.05); higher erythrocyte sedimentation rate and immunoglobulin M levels (p < 0.05); higher prevalence of leukopenia, neutropenia, anemia, low complement 3, and low complement 4 (p < 0.05); and higher titers of antinuclear antibody, anti-Sjögren syndrome A, anti-Ro52, and rheumatoid factor positivity (p < 0.05) than men, whereas men with pSS had a higher prevalence of parotid enlargement and interstitial lung disease (p < 0.05). Conclusions: Women with pSS are associated with more dryness, cytopenia, hypocomplementemia, and autoantibody positivity. Although men with pSS probably have lighter sicca symptoms and lower immunoactivity and serologic responses, regular monitoring of interstitial lung disease in men is vital.
- 27 February 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 1999-2011
Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
Various biological disease-modifying anti-rheumatic drugs (bDMARDs) have been applied for treating axial spondyloarthritis (axSpA). However, there is a glaring absence of a bibliometric analysis on bDMARDs against axSpA. Articles related to use of bDMARDs in treating axSpA published from 2004 to 2022 were searched from the Web of Science Core Collection. VOS viewer 1.6.18 and CiteSpace 6.1.R2 were used to analyze and visualize the quantity and citations of publications, as well as to identify “research hotspots” and trends in this field. BibExcel version 1.0.0 and gCLUTO version 1.0 were used to build matrices for bi-clustering analysis. A total of 2546 articles referring to bDMARDs for treatment of axSpA were included in this bibliometric analysis. Overall, the number of publications has been increasing steadily annually. The USA (23.21%, 591 publications) ranked first with the largest output of papers, followed by Germany, and the Netherlands. Rheumazentrum Ruhrgebiet ranked first as the most frequent publisher (119 articles). Annals of the Rheumatic Diseases published the most documents (6.76%, 172 publications) in this field. The predominant hotspots have been “tuberculosis,” “IL-17,” and “quality of life” in the field until 2020. Since 2015, “biosimilar pharmaceuticals” has retained the popularity. Current research hotspots are “spinal radiographic progression,” Janus kinase (JAK) inhibitors, and adverse events (AEs). Machine learning has become popular gradually. Globally, there has been a steady increase in the number of studies on bDMARDs use against axSpA. JAK inhibitors, spinal radiographic progression, biosimilar pharmaceuticals, and AEs are current research hotspots. Machine learning is emerging research hotspots and trends in this field.
- 27 February 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 1999-2011
Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
Various biological disease-modifying anti-rheumatic drugs (bDMARDs) have been applied for treating axial spondyloarthritis (axSpA). However, there is a glaring absence of a bibliometric analysis on bDMARDs against axSpA. Articles related to use of bDMARDs in treating axSpA published from 2004 to 2022 were searched from the Web of Science Core Collection. VOS viewer 1.6.18 and CiteSpace 6.1.R2 were used to analyze and visualize the quantity and citations of publications, as well as to identify “research hotspots” and trends in this field. BibExcel version 1.0.0 and gCLUTO version 1.0 were used to build matrices for bi-clustering analysis. A total of 2546 articles referring to bDMARDs for treatment of axSpA were included in this bibliometric analysis. Overall, the number of publications has been increasing steadily annually. The USA (23.21%, 591 publications) ranked first with the largest output of papers, followed by Germany, and the Netherlands. Rheumazentrum Ruhrgebiet ranked first as the most frequent publisher (119 articles). Annals of the Rheumatic Diseases published the most documents (6.76%, 172 publications) in this field. The predominant hotspots have been “tuberculosis,” “IL-17,” and “quality of life” in the field until 2020. Since 2015, “biosimilar pharmaceuticals” has retained the popularity. Current research hotspots are “spinal radiographic progression,” Janus kinase (JAK) inhibitors, and adverse events (AEs). Machine learning has become popular gradually. Globally, there has been a steady increase in the number of studies on bDMARDs use against axSpA. JAK inhibitors, spinal radiographic progression, biosimilar pharmaceuticals, and AEs are current research hotspots. Machine learning is emerging research hotspots and trends in this field.